NBQX disodium salt - CAS 479347-86-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
The sodium salt form of NBQX, which has been found to be an AMPA receptor antagonist and could be used as neuroprotective as well as anticonvulsant agent.
≥98% by HPLC
Dark Brown Solid
NBQX Disodium; NBQX 2Na; 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt
Canonical SMILES:
1.Effects of AMPA-receptor and voltage-sensitive sodium channel blockade on high potassium-induced glutamate release and neuronal death in vivo.
Wu A;Fujikawa DG Brain Res. 2002 Aug 9;946(1):119-29.
High extracellular potassium induces spreading depression-like depolarizations and elevations of extracellular glutamate. Both occur in the penumbra of a focal ischemic infarct, and may be responsible for the spread of cell death from the infarct core to the penumbra. We have modeled this situation with microdialysis of an isotonic high-potassium solution into the normal rat amygdala for 70 min. This elevates extracellular glutamate up to 8-fold or more and produces irreversibly damaged, acidophilic neurons. NMDA-receptor blockade protects neurons and reduces the elevation of extracellular glutamate. Here we investigated the effects of sodium channel blockade with the voltage-sensitive sodium channel blocker tetrodotoxin and the AMPA receptor antagonist 2,3-dihydroxy-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-sulfonamide disodium (NBQX disodium) on high potassium-induced neuronal death and extracellular glutamate elevations. The acidophilic neurons produced are necrotic by ultrastructural examination. Tetrodotoxin, at dialysate concentrations of 33, 330 and 3300 microM (only a small fraction is extracted by tissue), markedly reduced the elevations of glutamate in rat amygdala at nearly all time points during high-potassium perfusion, but it reduced tissue edema only at the highest concentration, and it was neuroprotective only if dialyzed prior to high-potassium microdialysis (at 330 microM concentration).
2.Involvement of ionotropic glutamate receptors in low frequency electroacupuncture analgesia in rats.
Choi BT;Lee JH;Wan Y;Han JS Neurosci Lett. 2005 Apr 4;377(3):185-8. Epub 2004 Dec 29.
The present study was conducted to determine whether blockage of both N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid/kainate (AMPA/KA) receptors influences the induction of low frequency electroacupuncture (EA) analgesia. Although neither intrathecal injection of NMDA antagonist D-2-amino-5-phosphonopentanoic acid (D-AP-5) or AMPA/KA antagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonami-de (NBQX) disodium alone had an effect on analgesia, spinal application of D-AP-5 and NBQX disodium significantly prevented analgesia induced by 2 Hz EA. The intrathecal injection of the excitatory amino acid NMDA produced analgesia for several minutes after intrathecal injection, as did EA stimulation. These results suggest that ionotropic glutamate receptors may be involved in the induction of 2 Hz EA analgesia.
3.Pharmacological characterization of harmaline-induced tremor activity in mice.
Paterson NE;Malekiani SA;Foreman MM;Olivier B;Hanania T Eur J Pharmacol. 2009 Aug 15;616(1-3):73-80. doi: 10.1016/j.ejphar.2009.05.031. Epub 2009 Jun 2.
Harmaline-induced tremor in rodents is a model of essential tremor. We utilized a novel assay to quantify tremor activity in mice and found that tremor activity was dependent on harmaline dose. The first-line clinical essential tremor treatments propranolol, primidone and gabapentin and gamma-hydroxybutyrate (GHB) significantly attenuated harmaline-induced tremor. The anticonvulsants valproate and carbamazepine and the mood stabilizer lithium suppressed harmaline-induced tremor. The gamma-amino-butyric acid (GABA) receptor subtype A receptor agonist muscimol attenuated harmaline-induced tremor. By contrast, the GABA(B) receptor agonist R-baclofen increased tremor at the lowest dose tested, but had no effects at higher doses. Administration of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists phencyclidine or 5R,10S-(+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine hydrogen maleate (MK-801) attenuated harmaline-induced tremor. The competitive NMDA antagonist D-4-[(2E)-3-phosphono-2-propenyl]-2-piperazinecarboxylic acid (d-CPPene) dose-dependently blocked harmaline-induced tremor, as did the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt (NBQX).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related AMPAR Products

CAS 211735-76-1 Farampator

(CAS: 211735-76-1)

Farampator, also called as CX-691 or Org24448, is an AMPA receptor positive allosteric modulator and glycine reuptake inhibitor potentially for the treatment of...

(CAS: 177314-99-7)

LY-326325, a decahydroisoquinaline derivative, has been found to be an AMPA receptor antagonist and was once studied for neuroprotection.

CAS 157115-85-0 Noopept

(CAS: 157115-85-0)

Noopept is a nootropic and neuroprotective drug that normalizes the balance of the pro- and antioxidant systems. Noopept modulates a variety of physiological fu...

CAS 83654-13-1 (R)-AMPA

(CAS: 83654-13-1)

(R)-AMPA is an inactive enantiomer of AMPA, which has been found to be a definitive agonist of the AMPA glutamatergic ionotropic receptor.

CAS 77472-70-9 4-Phenyl-2-pyrrolidone-1-acetamide

(CAS: 77472-70-9)

4-Phenyl-2-pyrrolidone-1-acetamide is a GABA derivative that exhibited apparent immunocorrection properties during immunosuppression induced by cyclophosphamide...

CAS 143691-37-6 LY 293606

LY 293606
(CAS: 143691-37-6)

GYKI-53405 is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA receptor) antagonist. It can bind to Xenopus brain membranes ...

GYKI 47261 dihydrochloride
(CAS: 1217049-32-5)

This active molecular is Non-competitiv a AMPA antagonist with IC50 value of 2.5 μM. GYKI-47261 is also a CYP2E1 inducer. GYKI-47261 showed broad spectrum of an...

CAS 215923-54-9 CX546

(CAS: 215923-54-9)

It is one of a series of AMPA modulators for the potential treatment of Alzheimer's disease, schizophrenia, and mild cognitive impairment (MCI). An ampakine dru...

Chemical Structure

CAS 479347-86-9 NBQX disodium salt

Quick Inquiry

Verification code

Featured Items